Pharmetheus
Richard Anziano has extensive experience in the field of statistics, particularly in the area of drug development. Richard worked as the Chief Statistician at Pharmetheus since March 2019. Prior to that, they operated their own statistical consulting business called Anziano Statistical Consulting, where they provided expertise in various aspects of drug development, such as US and EU Filings, quantitative decision making, business development, and organizational leadership. Richard also served as Pfizer's Vice President, Global Statistics Head, and Chief Statistician for 5 years, where they were responsible for leading a team of over 250 statisticians and overseeing a budget of 55M. In this role, they focused on driving the strategic direction for the group and establishing best practices for Data Monitoring Committees. Anziano has a strong background in therapeutic areas including Neuroscience, Cardiovascular, Inflammation, Infectious Disease, and Rare Disease.
Richard Anziano holds a Master of Science degree in Statistics from the University of Connecticut. Richard also attended Xavier High School, though no specific degree or field of study was mentioned.
This person is not in any offices
Pharmetheus
We are a consultancy firm offering services focused on the application of quantitative approaches to support drug research, development, and life-cycle decisions with the overall aim to improve patients’ lives. Our story began in 2012, when a team composed of experienced consultants, leaders from the pharmaceutical industry and researchers from Uppsala University formed Pharmetheus, Since then, our core business focus has broadened to support a wider range of model informed drug development (MIDD) activities across all phases of research and development and across a wide range of therapeutic areas. We continue to provide fit for purpose analyses and reports to support a wide variety of drug development decisions (such as dose selection, developing pediatric development plans, investigating the potential risk for QTc prolongation etc.). Read more at www.pharmetheus.com